{
  "ticker": "RANI",
  "analysis_date": "2025-07-26T23:34:12.338834",
  "total_filings_analyzed": 12,
  "detailed_filings": [
    {
      "form": "8-K",
      "filing_date": "2025--",
      "accession_number": "0000950170-25-070344",
      "company_name": "Company Name",
      "filing_url": "https://www.sec.gov/Archives/edgar/data/0000950170-25-070344",
      "content": "<SEC-DOCUMENT>0000950170-25-070344.txt : 20250513\n<SEC-HEADER>0000950170-25-070344.hdr.sgml : 20250513\n<ACCEPTANCE-DATETIME>20250513161016\nACCESSION NUMBER:\t\t0000950170-25-070344\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t13\nCONFORMED PERIOD OF REPORT:\t20250513\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20250513\nDATE AS OF CHANGE:\t\t20250513\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tRani Therapeutics Holdings, Inc.\n\t\tCENTRAL INDEX KEY:\t\t\t0001856725\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tORGANIZATION NAME:           \t03 Life Sciences\n\t\tEIN:\t\t\t\t000000000\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1231\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-40672\n\t\tFILM NUMBER:\t\t25940160\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n\t\tBUSINESS PHONE:\t\t(408) 457-3700\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n</SEC-HEADER>\n<DOCUMENT>\n<TYPE>8-K\n<SEQUENCE>1\n<FILENAME>rani-20250513.htm\n<DESCRIPTION>8-K\n<TEXT>\n<XBRL>\n<?xml version='1.0' encoding='ASCII'?>\n<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->\n<!-- Creation Date :2025-05-13T12:33:27.6138+00:00 -->\n<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:xbrldi=\"http://xbrl.org/2006/xbrldi\" xmlns:xbrldt=\"http://xbrl.org/2005/xbrldt\" xmlns:xbrli=\"http://www.xbrl.org/2003/instance\" xmlns:link=\"http://www.xbrl.org/2003/linkbase\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:ix=\"http://www.xbrl.org/2013/inlineXBRL\" xmlns:nonNumeric=\"http://www.xbrl.org/dtr/type/non-numeric\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dei=\"http://xbrl.sec.gov/dei/2024\" xmlns:rani=\"http://www.ranitherapeutics.com/20250513\" xmlns:ixt-sec=\"http://www.sec.gov/inlineXBRL/transformation/2015-08-31\" xmlns:ixt=\"http://www.xbrl.org/inlineXBRL/transformation/2022-02-16\">\n <head>\n  <title>8-K</title>\n  <meta http-equiv=\"Content-Type\" content=\"text/html\"/>\n </head>\n <body style=\"padding:8px;margin:auto!important;z-index:0;position:relative;\">\n  <div style=\"display:none;\"><ix:header><ix:hidden><ix:nonNumeric id=\"F_6484f487-12f4-480d-a249-5b1fc40d3bcf\" name=\"dei:AmendmentFlag\" contextRef=\"C_ab6b5228-6db9-4490-9e12-33d7c9bc9702\">false</ix:nonNumeric><ix:nonNumeric id=\"F_7ac990a2-7c32-481e-b348-7a4f062df113\" name=\"dei:EntityCentralIndexKey\" contextRef=\"C_ab6b5228-6db9-4490-9e12-33d7c9bc9702\">0001856725</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type=\"simple\" xlink:href=\"rani-20250513.xsd\"/></ix:references><ix:resources><xbrli:context id=\"C_ab6b5228-6db9-4490-9e12-33d7c9bc9702\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-13</xbrli:startDate><xbrli:endDate>2025-05-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>\n  <div style=\"z-index:2;min-height:0.5in;position:relative;\"></div>\n  <div class=\"main-content-container\" style=\"z-index:5;position:relative;\"><p style=\"border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">WASHINGTON, D.C. 20549</span></p><p style=\"margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><h2 style=\"font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">FORM </span><span style=\"font-size:18pt;font-family:Times New Roman;\"><ix:nonNumeric id=\"F_4a55926b-e006-4197-9b07-d83d150599ee\" contextRef=\"C_ab6b5228-6db9-4490-9e12-33d7c9bc9702\" name=\"dei:DocumentType\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">8-K</span></ix:nonNumeric></span></h2><p style=\"margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">CURRENT REPORT</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">Pursuant to Section 13 or 15(d) of</span><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\"> </span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">the Securities Exchange Act of 1934</span></p>\n   <table style=\"border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;\">\n    <tr style=\"visibility:collapse;\">\n     <td style=\"width:100%;box-sizing:content-box;\"/>\n    </tr>\n    <tr style=\"height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;\">\n     <td style=\"padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;\"><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;\">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id=\"F_5d23b2c6-cae1-449f-91b5-ec07dc8d6aef\" contextRef=\"C_ab6b5228-6db9-4490-9e12-33d7c9bc9702\" name=\"dei:DocumentPeriodEndDate\" format=\"ixt:date-monthname-day-year-en\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;\">May 13, 2025</span></ix:nonNumeric></span></p></td>\n    </tr>\n   </table><p style=\"margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"font-size:24pt;font-family:Times New Roman;\"><ix:nonNumeric id=\"F_26e6c52e-9823-4709-b299-4204eca319fb\" contextRef=\"C_ab6b5228-6db9-4490-9e12-33d7c9bc9702\" name=\"dei:EntityRegistrantName\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">Rani Therapeutics Holdings, Inc.</span></ix:nonNumeric></span></p><p style=\"font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">(Exact name of registrant as specified in its charter)</span></p><p style=\"margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p>\n   <table style=\"border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;\">\n    <tr style=\"visibility:collapse;\">\n     <td style=\"width:20%;box-sizing:content-box;\"/>\n     <td style=\"width:1%;box-sizing:content-box;\"/>\n     <td style=\"width:20%;box-sizing:content-box;\"/>\n     <td style=\"width:18%;box-sizing:content-box;\"/>\n     <td style=\"width:41%;box-sizing:content-box;\"/>\n    </tr>\n    <tr style=\"height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;\">\n     <td colspan=\"3\" style=\"padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;\"><p style=\"font-size:10pt;margin-top",
      "ai_summary": "### Summary of Rani Therapeutics Holdings, Inc. 8-K Filing (May 13, 2025)  \n\n1. **Key Business Events**: The filing reports operational and financial results, likely including updates on clinical trials or pipeline progress for Rani’s oral biologic drug delivery platform.  \n\n2. **Financial Highlights/Concerns**: While specific figures aren’t provided in the preview, the 8-K signals material financial disclosures, potentially revenue, R&D expenses, or liquidity updates. Investors should review attached exhibits for details.  \n\n3. **Strategic Decisions**: No explicit strategic shifts are mentioned, but the filing may hint at partnerships, trial milestones, or funding activities given the biopharma focus.  \n\n4. **Regulatory/Compliance**: Standard SEC compliance is confirmed, with no flagged issues. The filing aligns with reporting obligations under the 1934 Act.  \n\n5. **Investor Impact**: The update is material enough to warrant an 8-K, suggesting significant developments affecting valuation or operational outlook. Stakeholders should monitor for clinical progress or financial health signals.  \n\n*Note: Full financials/exhibits (13 documents referenced) would provide granular details.*  \n\n**Word count**: ~150"
    },
    {
      "form": "8-K",
      "filing_date": "2025--",
      "accession_number": "0000950170-25-064624",
      "company_name": "Company Name",
      "filing_url": "https://www.sec.gov/Archives/edgar/data/0000950170-25-064624",
      "content": "<SEC-DOCUMENT>0000950170-25-064624.txt : 20250506\n<SEC-HEADER>0000950170-25-064624.hdr.sgml : 20250506\n<ACCEPTANCE-DATETIME>20250506171517\nACCESSION NUMBER:\t\t0000950170-25-064624\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t11\nCONFORMED PERIOD OF REPORT:\t20250501\nITEM INFORMATION:\t\tNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20250506\nDATE AS OF CHANGE:\t\t20250506\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tRani Therapeutics Holdings, Inc.\n\t\tCENTRAL INDEX KEY:\t\t\t0001856725\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tORGANIZATION NAME:           \t03 Life Sciences\n\t\tEIN:\t\t\t\t000000000\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1231\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-40672\n\t\tFILM NUMBER:\t\t25918313\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n\t\tBUSINESS PHONE:\t\t(408) 457-3700\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n</SEC-HEADER>\n<DOCUMENT>\n<TYPE>8-K\n<SEQUENCE>1\n<FILENAME>rani-20250501.htm\n<DESCRIPTION>8-K\n<TEXT>\n<XBRL>\n<?xml version='1.0' encoding='ASCII'?>\n<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->\n<!-- Creation Date :2025-05-06T17:06:06.7615+00:00 -->\n<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:xbrldi=\"http://xbrl.org/2006/xbrldi\" xmlns:xbrldt=\"http://xbrl.org/2005/xbrldt\" xmlns:xbrli=\"http://www.xbrl.org/2003/instance\" xmlns:link=\"http://www.xbrl.org/2003/linkbase\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:ix=\"http://www.xbrl.org/2013/inlineXBRL\" xmlns:nonNumeric=\"http://www.xbrl.org/dtr/type/non-numeric\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dei=\"http://xbrl.sec.gov/dei/2024\" xmlns:rani=\"http://www.ranitherapeutics.com/20250501\" xmlns:ixt-sec=\"http://www.sec.gov/inlineXBRL/transformation/2015-08-31\" xmlns:ixt=\"http://www.xbrl.org/inlineXBRL/transformation/2022-02-16\">\n <head>\n  <title>8-K</title>\n  <meta http-equiv=\"Content-Type\" content=\"text/html\"/>\n </head>\n <body style=\"padding:8px;margin:auto!important;z-index:0;position:relative;\">\n  <div style=\"display:none;\"><ix:header><ix:hidden><ix:nonNumeric id=\"F_11bf2ebc-f173-418c-a5ac-832ae401419e\" name=\"dei:AmendmentFlag\" contextRef=\"C_37a58634-f86a-4a60-84e4-c88cab7d6f82\">false</ix:nonNumeric><ix:nonNumeric id=\"F_06734979-09dd-4cc4-ad0b-90e62051b665\" name=\"dei:EntityCentralIndexKey\" contextRef=\"C_37a58634-f86a-4a60-84e4-c88cab7d6f82\">0001856725</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type=\"simple\" xlink:href=\"rani-20250501.xsd\"/></ix:references><ix:resources><xbrli:context id=\"C_37a58634-f86a-4a60-84e4-c88cab7d6f82\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>\n  <div style=\"z-index:2;min-height:0.5in;position:relative;\"></div>\n  <div class=\"main-content-container\" style=\"z-index:5;position:relative;\"><p style=\"border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">WASHINGTON, D.C. 20549</span></p><p style=\"margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><h2 style=\"font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">FORM </span><span style=\"font-size:18pt;font-family:Times New Roman;\"><ix:nonNumeric id=\"F_3e347d06-bbb3-47ba-81b4-027c8c064921\" contextRef=\"C_37a58634-f86a-4a60-84e4-c88cab7d6f82\" name=\"dei:DocumentType\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">8-K</span></ix:nonNumeric></span></h2><p style=\"margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">CURRENT REPORT</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">Pursuant to Section 13 or 15(d) of</span><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\"> </span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">the Securities Exchange Act of 1934</span></p>\n   <table style=\"border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;\">\n    <tr style=\"visibility:collapse;\">\n     <td style=\"width:100%;box-sizing:content-box;\"/>\n    </tr>\n    <tr style=\"height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;\">\n     <td style=\"padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;\"><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;\">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id=\"F_5d2e6cfc-19a2-499c-91bf-3959790a4b0a\" contextRef=\"C_37a58634-f86a-4a60-84e4-c88cab7d6f82\" name=\"dei:DocumentPeriodEndDate\" format=\"ixt:date-monthname-day-year-en\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;\">May 01, 2025</span></ix:nonNumeric></span></p></td>\n    </tr>\n   </table><p style=\"margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"font-size:24pt;font-family:Times New Roman;\"><ix:nonNumeric id=\"F_28960fb8-a68b-4e56-b3ef-8ac87854944f\" contextRef=\"C_37a58634-f86a-4a60-84e4-c88cab7d6f82\" name=\"dei:EntityRegistrantName\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">Rani Therapeutics Holdings, Inc.</span></ix:nonNumeric></span></p><p style=\"font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">(Exact name of registrant as specified in its charter)</span></p><p style=\"margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p>\n   <table style=\"border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;\">\n    <tr style=\"visibility:collapse;\">\n     <td style=\"width:20%;box-sizing:content-box;\"/>\n     <td style=\"width:1%;box-sizing:content-box;\"/>\n     <td style=\"width:20%;box-sizing:content-box;\"/>\n     <td style=\"width:18%;box-sizing:content-box;\"/>\n     <td style=\"width:41%;box-sizing:content-box;\"/>\n    </tr>\n    <tr style=\"height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;\">\n     <td colspan=\"3\" style=\"padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;p",
      "ai_summary": "### Summary of Rani Therapeutics Holdings, Inc. 8-K Filing (May 6, 2025)  \n\n1. **Key Business Event**: The filing discloses a **notice of delisting** or failure to meet a continued listing rule, indicating potential non-compliance with Nasdaq or exchange requirements.  \n\n2. **Financial Concerns**: The delisting notice suggests financial or operational challenges, possibly related to stock price, market capitalization, or other listing standards. No specific financial data is provided in this excerpt.  \n\n3. **Strategic Implications**: Delisting risks may force Rani Therapeutics to consider strategic alternatives, such as reverse stock splits, uplisting to another exchange, or private financing.  \n\n4. **Regulatory/Compliance**: The filing highlights a **regulatory breach**, likely tied to Nasdaq’s continued listing standards (e.g., minimum bid price, shareholder equity).  \n\n5. **Investor Impact**: Delisting could reduce liquidity, increase volatility, and diminish investor confidence. Shareholders may face challenges in trading shares if moved to OTC markets.  \n\n**Next Steps**: Investors should monitor subsequent filings for remediation plans or appeals to retain listing status. The lack of immediate financial details suggests further disclosures may follow.  \n\n*(Word count: 150)*"
    },
    {
      "form": "DEF 14A",
      "filing_date": "2025--",
      "accession_number": "0001140361-25-014078",
      "company_name": "Company Name",
      "filing_url": "https://www.sec.gov/Archives/edgar/data/0001140361-25-014078",
      "content": "<SEC-DOCUMENT>0001140361-25-014078.txt : 20250416\n<SEC-HEADER>0001140361-25-014078.hdr.sgml : 20250416\n<ACCEPTANCE-DATETIME>20250416080220\nACCESSION NUMBER:\t\t0001140361-25-014078\nCONFORMED SUBMISSION TYPE:\tDEF 14A\nPUBLIC DOCUMENT COUNT:\t\t18\nCONFORMED PERIOD OF REPORT:\t20250528\nFILED AS OF DATE:\t\t20250416\nDATE AS OF CHANGE:\t\t20250416\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tRani Therapeutics Holdings, Inc.\n\t\tCENTRAL INDEX KEY:\t\t\t0001856725\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tORGANIZATION NAME:           \t03 Life Sciences\n\t\tEIN:\t\t\t\t000000000\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1231\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\tDEF 14A\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-40672\n\t\tFILM NUMBER:\t\t25841261\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n\t\tBUSINESS PHONE:\t\t(408) 457-3700\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n</SEC-HEADER>\n<DOCUMENT>\n<TYPE>DEF 14A\n<SEQUENCE>1\n<FILENAME>ny20044394x1_def14a.htm\n<DESCRIPTION>DEF 14A\n<TEXT>\n<XBRL>\n<?xml version='1.0' encoding='ASCII'?>\n<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->\n<!-- Created: Wed Apr 16 12:02:08 UTC 2025 -->\n<html xmlns:compsci=\"http://compsciresources.com\" xmlns:dei=\"http://xbrl.sec.gov/dei/2024\" xmlns:dtr=\"http://www.xbrl.org/dtr/type/2022-03-31\" xmlns:ecd=\"http://xbrl.sec.gov/ecd/2024\" xmlns:iso4217=\"http://www.xbrl.org/2003/iso4217\" xmlns:ix=\"http://www.xbrl.org/2013/inlineXBRL\" xmlns:ixt=\"http://www.xbrl.org/inlineXBRL/transformation/2020-02-12\" xmlns:ixt-sec=\"http://www.sec.gov/inlineXBRL/transformation/2015-08-31\" xmlns:link=\"http://www.xbrl.org/2003/linkbase\" xmlns:rani=\"http://www.ranitherapeutics.com/20250528\" xmlns:us-types=\"http://xbrl.us/us-types/2009-01-31\" xmlns:xbrldi=\"http://xbrl.org/2006/xbrldi\" xmlns:xbrli=\"http://www.xbrl.org/2003/instance\" xmlns:xl=\"http://www.xbrl.org/2003/XLink\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:xs=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns=\"http://www.w3.org/1999/xhtml\"><head><title> </title>\n<meta content=\"text/html\" http-equiv=\"Content-Type\"/>\n</head><body><div style=\"color: #000000; \"><div>\n</div><!--Begin Page 1--><div>\n</div><div class=\"BRDSX_page\" style=\"text-align: left; margin: auto; line-height: initial; width: 540pt;\"><a id=\"ny20044394x1_def14a_100-regcov_pg1\"><!--Anchor--></a><p style=\"text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold\"><a href=\"#TOC\">TABLE OF CONTENTS</a></p><div class=\"BRDSX_block-frill\" style=\"width: 540pt; margin-left: 0pt;\"><div><div class=\"BRDSX_rule-full\" style=\"height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;\"> </div><div class=\"BRDSX_rule-full\" style=\"height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;\"> </div></div></div><div class=\"BRDSX_page-content\"><div class=\"BRDSX_block-main\" style=\"width: 540pt; margin-left: 0pt;\"><div class=\"BRDSX_h1\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;\">UNITED STATES <br/></div><div class=\"BRDSX_h1\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;\">SECURITIES AND EXCHANGE COMMISSION <br/></div><div class=\"BRDSX_h1\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 11pt;\"><span style=\"font-size: 11pt;\">Washington, D.C. 20549 </span></div><div class=\"BRDSX_h1\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 18.5pt; text-align: center;\"><span style=\"-sec-ix-hidden: hidden-fact-0\">SCHEDULE 14A</span><br/></div><div class=\"BRDSX_h1\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 10pt;\"><span style=\"font-size: 10pt; font-weight: normal;\">Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 </span><br/></div><div class=\"BRDSX_h1\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 10pt;\"><span style=\"font-size: 10pt; font-weight: normal;\">(Amendment No.<span style=\"text-decoration:underline\">&#8195;&#8195;</span>) </span></div><table cellpadding=\"0\" class=\"BRDSX_txttab\" style=\"border-spacing: 0;margin-top: 4pt; width: 540pt; margin-left: auto; margin-right: auto;\"><tr class=\"BRDSX_boxspacer\"><td style=\"height: 6pt; width: 216pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 12pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 288pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td></tr><tr><td style=\"width: 216pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;\"><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;\">Filed by the Registrant </div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 12pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;\"><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;\">&#9746; </div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 288pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;\"><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;\">&#160;</div></td></tr><tr><td style=\"width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: top;\"><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;\">Filed by a Party other than the Registrant </div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 12pt; padding-top: 1.34pt; text-align: left; vertical-align: bottom;\"><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;\">&#8201;<span style=\"font-size: 10pt;\">&#9744;</span></div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td></tr><tr class=\"BRDSX_boxspacer\"><td style=\"height: 2.75pt; width: 216pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 2.75pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 2.75pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 2.75pt; width: 12pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 2.75pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td></tr></table><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;\">Check the appropriate box: </div><table cellpadding=\"0\" class=\"BRDSX_txttab\" style=\"border-spacing: 0;margin-top: 4pt; width: 540pt; margin-left: auto; margin-right: auto;\"><tr class=\"BRDSX_boxspacer\"><td style=\"height: 6pt; width: 12pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"height: 6pt; width: 516pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td></tr><tr><td style=\"width: 12pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;\"><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;\">&#8201;<span style=\"font-size: 10pt;\">&#9744; </span></div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 516pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;\"><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;\">Preliminary Proxy Statement </div></td></tr><tr><td style=\"width: 12pt; padding-top: 1.34pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;\"><div class=\"BRDSX_fpara\" style=\"color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;\">&#8201;<span style=\"font-size: 10pt;\">&#9744; </span></div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 6pt;\"><div style=\"font-size: 1pt;\">&#8194;</div></td><td style=\"width: 516pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;\"><div class=\"BRDSX_fpara\" style=\"color",
      "ai_summary": "### Summary of Rani Therapeutics Holdings, Inc. DEF 14A Filing (2025)  \n\n1. **Key Business Events**: The filing is a definitive proxy statement (DEF 14A) for Rani Therapeutics, a biopharmaceutical company (SIC 2834), ahead of its annual meeting scheduled for May 28, 2025. Details likely include director elections, executive compensation, and shareholder proposals.  \n\n2. **Financial Highlights/Concerns**: While specific financials aren’t disclosed here, the filing’s focus on governance suggests scrutiny of executive pay or capital allocation, common for clinical-stage firms like Rani.  \n\n3. **Strategic Decisions**: Potential discussions on R&D progress (given its focus on oral biologic drug delivery) or financing strategies, though specifics require deeper review of the full document.  \n\n4. **Regulatory/Compliance**: Standard proxy compliance under the 1934 Act, with no immediate red flags. The filing confirms adherence to SEC reporting requirements.  \n\n5. **Investor Impact**: Shareholders will vote on governance matters, influencing oversight and strategic direction. The meeting’s outcomes could affect investor confidence, especially if contentious issues arise (e.g., compensation or board changes).  \n\n*Note*: Full analysis requires the complete document, but this proxy signals routine annual governance processes with no overt disruptions."
    },
    {
      "form": "8-K",
      "filing_date": "2025--",
      "accession_number": "0000950170-25-090384",
      "company_name": "Company Name",
      "filing_url": "https://www.sec.gov/Archives/edgar/data/0000950170-25-090384",
      "content": "<SEC-DOCUMENT>0000950170-25-090384.txt : 20250626\n<SEC-HEADER>0000950170-25-090384.hdr.sgml : 20250626\n<ACCEPTANCE-DATETIME>20250626160616\nACCESSION NUMBER:\t\t0000950170-25-090384\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t10\nCONFORMED PERIOD OF REPORT:\t20250620\nITEM INFORMATION:\t\tNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20250626\nDATE AS OF CHANGE:\t\t20250626\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tRani Therapeutics Holdings, Inc.\n\t\tCENTRAL INDEX KEY:\t\t\t0001856725\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tORGANIZATION NAME:           \t03 Life Sciences\n\t\tEIN:\t\t\t\t000000000\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1231\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-40672\n\t\tFILM NUMBER:\t\t251080405\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n\t\tBUSINESS PHONE:\t\t(408) 457-3700\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n</SEC-HEADER>\n<DOCUMENT>\n<TYPE>8-K\n<SEQUENCE>1\n<FILENAME>rani-20250620.htm\n<DESCRIPTION>8-K\n<TEXT>\n<XBRL>\n<?xml version='1.0' encoding='ASCII'?>\n<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->\n<!-- Creation Date :2025-06-26T15:56:38.5632+00:00 -->\n<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:xbrldi=\"http://xbrl.org/2006/xbrldi\" xmlns:xbrldt=\"http://xbrl.org/2005/xbrldt\" xmlns:xbrli=\"http://www.xbrl.org/2003/instance\" xmlns:link=\"http://www.xbrl.org/2003/linkbase\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:ix=\"http://www.xbrl.org/2013/inlineXBRL\" xmlns:nonNumeric=\"http://www.xbrl.org/dtr/type/non-numeric\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:dei=\"http://xbrl.sec.gov/dei/2025\" xmlns:rani=\"http://www.ranitherapeutics.com/20250620\" xmlns:ixt-sec=\"http://www.sec.gov/inlineXBRL/transformation/2015-08-31\" xmlns:ixt=\"http://www.xbrl.org/inlineXBRL/transformation/2022-02-16\">\n <head>\n  <title>8-K</title>\n  <meta http-equiv=\"Content-Type\" content=\"text/html\"/>\n </head>\n <body style=\"padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;\">\n  <div style=\"display:none;\"><ix:header><ix:hidden><ix:nonNumeric id=\"F_6f5879c5-84ec-4698-bd9b-89065e295977\" name=\"dei:EntityCentralIndexKey\" contextRef=\"C_49d59206-7b8e-462b-9324-b8f1dc816ca9\">0001856725</ix:nonNumeric><ix:nonNumeric id=\"F_09e0dc79-154b-4d6a-bc4c-07503f4fcada\" name=\"dei:AmendmentFlag\" contextRef=\"C_49d59206-7b8e-462b-9324-b8f1dc816ca9\">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type=\"simple\" xlink:href=\"rani-20250620.xsd\"/></ix:references><ix:resources><xbrli:context id=\"C_49d59206-7b8e-462b-9324-b8f1dc816ca9\"><xbrli:entity><xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-20</xbrli:startDate><xbrli:endDate>2025-06-20</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>\n  <div style=\"z-index:2;min-height:0.5in;position:relative;\"></div>\n  <div class=\"main-content-container\" style=\"z-index:5;position:relative;\"><p style=\"border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">WASHINGTON, D.C. 20549</span></p><p style=\"margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><h2 style=\"font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">FORM </span><span style=\"font-size:18pt;font-family:Times New Roman;\"><ix:nonNumeric id=\"F_148135ad-459c-4be7-90b6-5652c9d98b58\" contextRef=\"C_49d59206-7b8e-462b-9324-b8f1dc816ca9\" name=\"dei:DocumentType\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">8-K</span></ix:nonNumeric></span></h2><p style=\"margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">CURRENT REPORT</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">Pursuant to Section 13 or 15(d) of</span><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\"> </span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">the Securities Exchange Act of 1934</span></p>\n   <table style=\"border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;\">\n    <tr style=\"visibility:collapse;\">\n     <td style=\"width:100%;box-sizing:content-box;\"/>\n    </tr>\n    <tr style=\"height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;\">\n     <td style=\"padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;\"><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.398%;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;\">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id=\"F_76202f96-1475-4fff-9ef1-7a2ef9ec0d68\" contextRef=\"C_49d59206-7b8e-462b-9324-b8f1dc816ca9\" name=\"dei:DocumentPeriodEndDate\" format=\"ixt:date-monthname-day-year-en\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;\">June 20, 2025</span></ix:nonNumeric></span></p></td>\n    </tr>\n   </table><p style=\"margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"font-size:24pt;font-family:Times New Roman;\"><ix:nonNumeric id=\"F_f1e2aae3-3120-44f7-b054-e9bc76ecaddc\" contextRef=\"C_49d59206-7b8e-462b-9324-b8f1dc816ca9\" name=\"dei:EntityRegistrantName\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">Rani Therapeutics Holdings, Inc.</span></ix:nonNumeric></span></p><p style=\"font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;\"><span style=\"color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">(Exact name of registrant as specified in its charter)</span></p><p style=\"margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p><p style=\"font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;\"><span style=\"white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;\">&#160;</span></p>\n   <table style=\"border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;\">\n    <tr style=\"visibility:collapse;\">\n     <td style=\"width:20%;box-sizing:content-box;\"/>\n     <td style=\"width:1%;box-sizing:content-box;\"/>\n     <td style=\"width:20%;box-sizing:content-box;\"/>\n     <td style=\"width:18%;box-sizing:content-box;\"/>\n     <td style=\"width:41%;box-sizing:content-box;\"/>\n    </tr>\n    <tr style=\"height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;\">\n     <td colspan=\"3\" style=\"padding-top:0.01in;padding-left:0in;vertica",
      "ai_summary": "### Summary of Rani Therapeutics Holdings, Inc. 8-K Filing (June 26, 2025):  \n\n1. **Key Business Event**: The filing indicates a **notice of delisting or failure to satisfy a continued listing rule** (Item 3.01), suggesting the company may no longer meet exchange requirements (e.g., Nasdaq minimum bid price or market cap rules).  \n\n2. **Financial Concerns**: While financial statements aren’t detailed here, the delisting notice implies potential financial distress or non-compliance with exchange standards, which could signal liquidity or operational challenges.  \n\n3. **Strategic Impact**: Delisting risks may force Rani Therapeutics to consider alternatives like a reverse stock split, uplisting to OTC markets, or pursuing private financing. Investor confidence could be affected.  \n\n4. **Regulatory Compliance**: The filing highlights a breach of listing standards, triggering SEC disclosure obligations. The company may need to submit a remediation plan to the exchange.  \n\n5. **Stakeholder Impact**: Shareholders face heightened volatility, reduced liquidity, and potential dilution if corrective measures (e.g., share consolidation) are pursued. Creditors and partners may reassess engagements.  \n\n**Next Steps**: Monitor for follow-up filings detailing remediation plans or financial restructuring. The delisting process timeline and appeals (if any) will be critical.  \n\n*Word count: 200*"
    },
    {
      "form": "8-K",
      "filing_date": "2025--",
      "accession_number": "0001193125-25-122872",
      "company_name": "Company Name",
      "filing_url": "https://www.sec.gov/Archives/edgar/data/0001193125-25-122872",
      "content": "<SEC-DOCUMENT>0001193125-25-122872.txt : 20250520\n<SEC-HEADER>0001193125-25-122872.hdr.sgml : 20250520\n<ACCEPTANCE-DATETIME>20250520085910\nACCESSION NUMBER:\t\t0001193125-25-122872\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t14\nCONFORMED PERIOD OF REPORT:\t20250520\nITEM INFORMATION:\t\tEntry into a Material Definitive Agreement\nITEM INFORMATION:\t\tUnregistered Sales of Equity Securities\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20250520\nDATE AS OF CHANGE:\t\t20250520\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tRani Therapeutics Holdings, Inc.\n\t\tCENTRAL INDEX KEY:\t\t\t0001856725\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tPHARMACEUTICAL PREPARATIONS [2834]\n\t\tORGANIZATION NAME:           \t03 Life Sciences\n\t\tEIN:\t\t\t\t000000000\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1231\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t001-40672\n\t\tFILM NUMBER:\t\t25966414\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n\t\tBUSINESS PHONE:\t\t(408) 457-3700\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t2051 RINGWOOD AVENUE\n\t\tCITY:\t\t\tSAN JOSE\n\t\tSTATE:\t\t\tCA\n\t\tZIP:\t\t\t95131\n</SEC-HEADER>\n<DOCUMENT>\n<TYPE>8-K\n<SEQUENCE>1\n<FILENAME>d945177d8k.htm\n<DESCRIPTION>8-K\n<TEXT>\n<XBRL>\n<?xml version='1.0' encoding='ASCII'?>\n<html xmlns:dei=\"http://xbrl.sec.gov/dei/2024\" xmlns:us-types=\"http://fasb.org/us-types/2024\" xmlns:nonnum=\"http://www.xbrl.org/dtr/type/non-numeric\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:link=\"http://www.xbrl.org/2003/linkbase\" xmlns:rani=\"http://www.ranitherapeutics.com/20250520\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" xmlns:utr=\"http://www.xbrl.org/2009/utr\" xmlns:iso4217=\"http://www.xbrl.org/2003/iso4217\" xmlns:ix=\"http://www.xbrl.org/2013/inlineXBRL\" xmlns:ixt=\"http://www.xbrl.org/inlineXBRL/transformation/2015-02-26\" xmlns:ixt-sec=\"http://www.sec.gov/inlineXBRL/transformation/2015-08-31\" xmlns:xbrli=\"http://www.xbrl.org/2003/instance\" xmlns:xbrldi=\"http://xbrl.org/2006/xbrldi\" xmlns=\"http://www.w3.org/1999/xhtml\">\n<head>\n<title>8-K</title>\n<meta http-equiv=\"Content-Type\" content=\"text/html\"/>\n</head>\n   <body><div style=\"display:none\"> <ix:header> <ix:hidden> <ix:nonNumeric name=\"dei:AmendmentFlag\" contextRef=\"duration_2025-05-20_to_2025-05-20\" id=\"ixv-292\">false</ix:nonNumeric> <ix:nonNumeric id=\"Hidden_dei_EntityCentralIndexKey\" name=\"dei:EntityCentralIndexKey\" contextRef=\"duration_2025-05-20_to_2025-05-20\">0001856725</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink=\"http://www.w3.org/1999/xlink\" xmlns:link=\"http://www.xbrl.org/2003/linkbase\" xlink:type=\"simple\" xlink:href=\"rani-20250520.xsd\" xlink:arcrole=\"http://www.xbrl.org/2003/linkbase\"/> </ix:references> <ix:resources> <xbrli:context id=\"duration_2025-05-20_to_2025-05-20\"> <xbrli:entity> <xbrli:identifier scheme=\"http://www.sec.gov/CIK\">0001856725</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-05-20</xbrli:startDate> <xbrli:endDate>2025-05-20</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style=\"text-align:center\"> <div style=\"width:8.5in;text-align:left;margin-left: auto;margin-right: auto\"> <div style=\"line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000\">&#160;</div> <div style=\"line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000\">&#160;</div> <p style=\"margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center\">UNITED STATES</p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center\">SECURITIES AND EXCHANGE COMMISSION</p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center\">WASHINGTON, D.C. 20549</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">&#160;</p> <div style=\"text-align:center\"> <div style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto\">&#160;</div></div> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center\">FORM <ix:nonNumeric name=\"dei:DocumentType\" contextRef=\"duration_2025-05-20_to_2025-05-20\" id=\"ixv-303\">8-K</ix:nonNumeric></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">&#160;</p> <div style=\"text-align:center\"> <div style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto\">&#160;</div></div> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center\">CURRENT REPORT</p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center\">Pursuant to Section&#160;13 or 15(d) of</p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center\">the Securities Exchange Act of 1934</p> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center\">Date of Report (Date of earliest event reported): <ix:nonNumeric name=\"dei:DocumentPeriodEndDate\" contextRef=\"duration_2025-05-20_to_2025-05-20\" format=\"ixt:datemonthdayyearen\" id=\"ixv-304\">May 20, 2025</ix:nonNumeric></p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">&#160;</p> <div style=\"text-align:center\"> <div style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto\">&#160;</div></div> <p style=\"margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center\"><ix:nonNumeric name=\"dei:EntityRegistrantName\" contextRef=\"duration_2025-05-20_to_2025-05-20\" id=\"ixv-305\">Rani Therapeutics Holdings, Inc.</ix:nonNumeric></p> <p style=\"margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center\">(Exact name of registrant as specified in its charter)</p> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">&#160;</p> <div style=\"text-align:center\"> <div style=\"line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto\">&#160;</div></div> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">&#160;</p>\n<table cellspacing=\"0\" cellpadding=\"0\" style=\"border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto\">\n<tr>\n<td style=\"width:34%\"/>\n<td style=\"vertical-align:bottom\"/>\n<td style=\"width:32%\"/>\n<td style=\"vertical-align:bottom;width:1%\"/>\n<td style=\"width:32%\"/></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td style=\"vertical-align:top;text-align:center\"><span style=\"font-weight:bold\"><ix:nonNumeric name=\"dei:EntityIncorporationStateCountryCode\" contextRef=\"duration_2025-05-20_to_2025-05-20\" format=\"ixt-sec:stateprovnameen\" id=\"ixv-306\">Delaware</ix:nonNumeric></span></td>\n<td style=\"vertical-align:bottom\">&#160;</td>\n<td style=\"vertical-align:top;text-align:center\"><span style=\"font-weight:bold\"><ix:nonNumeric name=\"dei:EntityFileNumber\" contextRef=\"duration_2025-05-20_to_2025-05-20\" id=\"ixv-307\">001-40672</ix:nonNumeric></span></td>\n<td style=\"vertical-align:bottom\">&#160;</td>\n<td style=\"vertical-align:top;text-align:center\"><span style=\"font-weight:bold\"><ix:nonNumeric name=\"dei:EntityTaxIdentificationNumber\" contextRef=\"duration_2025-05-20_to_2025-05-20\" id=\"ixv-308\">86-3114789</ix:nonNumeric></span></td></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt\">\n<td style=\"vertical-align:top;text-align:center\"><span style=\"font-weight:bold\">(State or other jurisdiction<br/>of incorporation)</span></td>\n<td style=\"vertical-align:bottom\">&#160;</td>\n<td style=\"vertical-align:top;text-align:center\"><span style=\"font-weight:bold\">(Commission<br/>File Number)</span></td>\n<td style=\"vertical-align:bottom\">&#160;</td>\n<td style=\"vertical-align:top;text-align:center\"><span style=\"font-weight:bold\">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style=\"font-size:12pt;margin-top:0pt;margin-bottom:0pt\">&#160;</p>\n<table cellspacing=\"0\" cellpadding=\"0\" style=\"border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto\">\n<tr>\n<td style=\"width:50%\"/>\n<td style=\"vertical-align:bottom;width:1%\"/>\n<td style=\"width:49%\"/></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td style=\"vertical-align:top;text-align:center\"><span style=\"font-weight:bold\"><ix:nonNumeric name=\"dei:EntityAddressAddressLine1\" contextRef=\"duration_2025-05-20_to_2025-05-20\" id=\"ixv-309\">2051 Ringwood Avenue</ix:nonNumeric></span></td>\n<td style=\"vertical-align:bottom\">&#160;</td>\n<td style=\"vertical-align:top\"/></tr>\n<tr style=\"page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt\">\n<td style=\"vertical-align:bottom;text-align:center\"><span style=\"font-weight:bold\"><ix:nonNumeric name=\"dei:EntityAddressCityOrTown\" contextRef=\"duration_2025-05-20_to_2025-05-20\" id=\"ixv-310\">San Jose</ix:nonNumeric>, <ix:nonNumeric name=\"dei:EntityAddressStateOrProvince\" contextRef=\"duration_2025-05-20_to_2025-05-20\" format=\"ixt-sec:stateprovnameen\" id=\"ixv-311\">California</ix:nonNumeric></span></td>\n<td style=\"vertical-align:bottom\">&#160;</td>\n<td style=\"vertical-align:bottom;text-align:center\"><span style=\"font-weight:bold\"><ix:nonNumeric name=\"dei:EntityAddressPostalZipCode\" contextRef=\"duration_2025-05-20_to_2025-05-20\" id=\"ixv-312\">95131</ix:nonNumeric></span></td></tr>\n<tr style=\"page-break-",
      "ai_summary": "### **Summary of Rani Therapeutics Holdings, Inc. 8-K Filing (May 20, 2025)**  \n\n1. **Key Business Events**:  \n   - The filing indicates **entry into a material definitive agreement** (details undisclosed in preview).  \n   - **Unregistered sales of equity securities** suggest a private placement or financing activity.  \n\n2. **Financial Highlights/Concerns**:  \n   - No explicit financial data in the preview, but the unregistered equity sales may imply capital-raising efforts, possibly for R&D or operational needs.  \n\n3. **Strategic Decisions**:  \n   - Potential strategic partnership or financing move, given the material agreement and equity issuance.  \n\n4. **Regulatory/Compliance Matters**:  \n   - The unregistered securities offering likely falls under **Rule 506(b) or 506(c)** of Regulation D, exempt from full SEC registration.  \n\n5. **Investor Impact**:  \n   - New agreements or financing could signal growth initiatives but may dilute existing shareholders if equity was issued.  \n\n**Conclusion**: This 8-K highlights strategic moves (agreements, funding) but lacks specifics. Investors should monitor subsequent filings for details on the material agreement and use of proceeds.  \n\n*(Word count: ~150)*"
    }
  ],
  "comprehensive_analysis": {
    "company_overview": "Rani Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally administered biologics. The company leverages its proprietary RaniPill technology platform to transform injectable drugs into oral formulations, aiming to improve patient compliance and outcomes. Rani operates in the pharmaceutical sector, specifically targeting chronic diseases that require frequent injections.",
    "timeline_events": [
      {
        "date": "2025-03-31",
        "event_type": "financial",
        "title": "Annual 10-K Filing",
        "description": "Rani Therapeutics filed its annual report (10-K) for the fiscal year ending December 31, 2024. The filing provides a comprehensive overview of the company's financial health, operational performance, and strategic initiatives.",
        "impact": "high",
        "investor_significance": "The 10-K offers investors a detailed look at the company's financials, including revenue, expenses, and R&D progress, which are critical for assessing long-term viability."
      },
      {
        "date": "2025-04-09",
        "event_type": "regulatory",
        "title": "Change in Certifying Accountant",
        "description": "Rani Therapeutics reported a change in its certifying accountant in an 8-K filing. The company did not disclose the reasons for the change but noted that there were no disagreements with the former accountant.",
        "impact": "medium",
        "investor_significance": "Changes in auditors can sometimes signal underlying financial or governance issues, though the filing indicates no disputes, which may mitigate concerns."
      },
      {
        "date": "2025-04-16",
        "event_type": "strategic",
        "title": "Proxy Statement (DEF 14A) Filing",
        "description": "Rani filed its definitive proxy statement ahead of its annual shareholder meeting scheduled for May 28, 2025. The filing outlines proposals for shareholder votes, including director elections and executive compensation.",
        "impact": "medium",
        "investor_significance": "Proxy statements provide insights into corporate governance and executive compensation, which are key for evaluating management alignment with shareholder interests."
      },
      {
        "date": "2025-04-30",
        "event_type": "operational",
        "title": "Departure of Director",
        "description": "An 8-K filing disclosed the departure of a director and the appointment of a new officer, along with compensatory arrangements for certain executives.",
        "impact": "medium",
        "investor_significance": "Leadership changes can impact company strategy and operations, making this event noteworthy for investors monitoring management stability."
      },
      {
        "date": "2025-05-06",
        "event_type": "regulatory",
        "title": "Notice of Delisting Risk",
        "description": "Rani disclosed a notice of delisting or failure to satisfy a continued listing rule in an 8-K filing. The company did not provide specific details but indicated potential non-compliance with exchange standards.",
        "impact": "high",
        "investor_significance": "Delisting risks can severely impact stock liquidity and investor confidence, making this a critical event to monitor."
      },
      {
        "date": "2025-05-13",
        "event_type": "financial",
        "title": "Q1 2025 Earnings Release",
        "description": "Rani reported its Q1 2025 financial results in an 8-K filing, highlighting operational progress and financial performance.",
        "impact": "high",
        "investor_significance": "Quarterly earnings are pivotal for assessing the company's short-term performance and progress toward clinical milestones."
      },
      {
        "date": "2025-05-20",
        "event_type": "strategic",
        "title": "Material Agreement and Equity Sale",
        "description": "Rani entered into a material definitive agreement and conducted an unregistered sale of equity securities, as disclosed in an 8-K filing.",
        "impact": "high",
        "investor_significance": "Material agreements and equity sales can signal strategic partnerships or funding needs, both of which are critical for growth."
      },
      {
        "date": "2025-05-29",
        "event_type": "regulatory",
        "title": "Shareholder Voting Results",
        "description": "Rani disclosed the results of matters submitted to a vote of security holders in an 8-K filing, including director elections and other proposals.",
        "impact": "medium",
        "investor_significance": "Voting results reflect shareholder sentiment and governance decisions, which can influence company direction."
      },
      {
        "date": "2025-06-26",
        "event_type": "regulatory",
        "title": "Second Notice of Delisting Risk",
        "description": "Rani filed another 8-K disclosing a notice of delisting or failure to satisfy a continued listing rule, indicating ongoing compliance issues.",
        "impact": "high",
        "investor_significance": "Repeated delisting warnings heighten concerns about the company's ability to maintain its exchange listing, posing significant risks."
      },
      {
        "date": "2025-07-16",
        "event_type": "operational",
        "title": "Other Events Disclosure",
        "description": "Rani filed an 8-K to disclose unspecified 'other events,' which may include clinical updates or strategic developments.",
        "impact": "low",
        "investor_significance": "While the details are unclear, such filings often precede material announcements, warranting investor attention."
      }
    ],
    "key_trends": [
      "Trend 1: Recurring delisting risks suggest potential financial or compliance challenges, which could undermine investor confidence.",
      "Trend 2: Frequent leadership and governance changes, including director departures and new appointments, indicate potential instability in management."
    ],
    "financial_highlights": [
      "Financial insight 1: The 10-K filing for 2024 provides a baseline for assessing annual performance, but subsequent filings (e.g., Q1 2025 earnings) will be critical for tracking progress.",
      "Financial insight 2: Unregistered equity sales in May 2025 suggest the company may be raising capital outside traditional markets, possibly to address liquidity needs."
    ],
    "risk_factors": [
      "Risk factor 1: Delisting risks could lead to reduced liquidity and increased volatility in the company's stock.",
      "Risk factor 2: Changes in certifying accountants and leadership may signal underlying governance or financial issues."
    ],
    "strategic_direction": "Rani Therapeutics appears to be navigating significant regulatory and financial challenges while advancing its RaniPill technology. The company's focus on oral biologics remains its core strategy, but recurring delisting risks and leadership changes could divert resources from R&D efforts.",
    "investment_thesis": "Key points for investment consideration include: (1) the potential of RaniPill technology to disrupt the biologics market, (2) the company's ability to address compliance and financial challenges, and (3) the stability of its leadership team. Investors should closely monitor upcoming clinical milestones and regulatory updates."
  },
  "metadata": {
    "analyzer": "DeepSeek Timeline Analyzer",
    "api_model": "deepseek-chat",
    "analysis_version": "1.0"
  }
}